TNF and Alzheimer disease: Further studies have reported that oral administration of JWH-133, a potent CB2R agonist, decreased microglial activation, proinflammatory factors COX-2 and tumor necrosis factor α (TNF-α) mRNA expression and the cortical levels of Aβ in a transgenic mouse model of AD [262].